Home›Stock Screener›Alivus Life Sciences›Financial Statements

Alivus Life Sciences Complete Financial Statements

9 Years of Data
2026 - 2018

In FY2026, Alivus Life Sciences (ALIVUS) reported revenue ₹2,552 Cr, net profit ₹567 Cr and EPS ₹45.99, with a net profit margin of 22.2% and ROE of 17.0%. Full financial statements from FY2018 to FY2026 (9 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see ALIVUS stock price BSE.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 22.22% 2026 data
EBITDA Margin 30.25% 2026 data
Operating Margin 30.00% 2026 data
Return on Assets 14.24% 2026 data
Return on Equity 17.02% 2026 data

Balance Sheet Ratios

Current Ratio 18.52 2026 data
Equity Ratio 83.66% 2026 data
Asset Turnover 0.64 2026 data

ALIVUS Revenue, Net Profit & EBITDA — Year-on-Year Growth

ALIVUS YoY (March 2025 vs March 2026) — revenue +5.4%, net profit +16.7%, EBITDA +7.7%, expenses +4.5%. Review Alivus Life Sciences P/E valuation to evaluate earnings-based valuation against sector peers.

Revenue Growth
+5.4%
Year-over-Year
Net Profit Growth
+16.7%
Year-over-Year
EBITDA Growth
+7.7%
Year-over-Year
Expense Growth
+4.5%
Year-over-Year
Assets Growth
+16.8%
Year-over-Year
Equity Growth
+18.3%
Year-over-Year
Operating Cash Flow Growth
-5.3%
Year-over-Year
Investing Cash Flow Growth
-426.5%
Year-over-Year
Financing Cash Flow Growth
+97.8%
Year-over-Year

ALIVUS Income Statement — Revenue, EBITDA & Net Profit

Alivus Life Sciences revenue ₹2,552 Cr, EBITDA ₹772 Cr, net profit ₹567 Cr, EPS ₹45.99 (2026) — net profit margin 22.2%. Explore ALIVUS intrinsic value to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018
Revenue 2,552 2,421 2,295 2,190 2,138 1,886 1,549 887 0
Expenses 1,780 1,704 1,609 1,519 1,507 1,294 1,065 639 0
EBITDA 772 717 686 671 631 592 484 248 0
Operating Profit Margin % 30.00% 29.00% 30.00% 30.00% 29.00% 31.00% 31.00% 28.00% -5.00%
Depreciation 75 61 54 42 38 33 29 19 0
Interest 5 2 2 1 28 88 34 1 0
Profit Before Tax 751 654 631 629 565 471 421 228 0
Tax 184 169 160 162 146 119 108 33 0
Net Profit 567 486 471 467 419 352 313 196 0
Earnings Per Share (₹) 45.99 39.63 38.43 38.11 35.63 32.61 29.04 24.64 -7.89

ALIVUS Balance Sheet — Assets, Liabilities & Shareholders' Equity

ALIVUS total assets ₹3,983 Cr, total equity ₹3,332 Cr, total liabilities ₹ Cr (2026) — ROE 17.0%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018
ASSETS
Total Assets 3,983 3,411 2,850 2,702 2,471 1,997 1,726 1,475 0
Current Assets 2,649 2,335 1,916 1,850 1,765 1,399 1,160 931 0
Fixed Assets 1,321 955 805 781 595 573 546 456 0
Capital Work in Progress 273 102 106 62 92 14 11 80 0
Investments 692 478 0 0 0 0 0 0 0
Other Assets 0 1,877 1,939 1,860 1,784 1,410 1,169 939 0
LIABILITIES
Total Liabilities
Current Liabilities 143 124 79 67 33 23 16 7 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 3,332 2,817 2,332 2,138 2,054 753 402 88 -1
Share Capital 25 25 25 25 25 2 2 2 0
Reserves & Surplus 3,308 2,793 2,308 2,114 2,030 751 400 86 -1

ALIVUS Cash Flow Statement — Operating, Investing & Financing

Alivus Life Sciences operating cash flow ₹392 Cr, investing ₹-616 Cr, financing ₹-6 Cr, net cash flow ₹-230 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018
Operating Activities 392 414 306 598 388 195 10 -1
Investing Activities -616 -117 -147 -122 -69 -51 -9 0
Financing Activities -6 -279 -388 -79 -214 -137 1 1
Net Cash Flow -230 18 -228 397 106 8 2 0